The Analyst Verdict: DexCom In The Eyes Of 4 Experts
Portfolio Pulse from Benzinga Insights
Four analysts have recently shared mixed evaluations of DexCom (NASDAQ:DXCM), with a consensus leaning towards a bullish outlook. The average 12-month price target for DexCom has been raised to $160.0, indicating a 7.15% increase from the previous target. Analysts from UBS, Citigroup, RBC Capital, and Raymond James have adjusted their ratings and price targets, reflecting optimism about DexCom's market performance and financial health. The company's revenue growth, net margin, ROE, and ROA have outperformed industry averages, although its debt management poses a challenge.
April 10, 2024 | 6:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
DexCom's stock is positively viewed by analysts, with an increased average price target of $160 and ratings upgrades from firms like UBS and Citigroup. The company's strong financial performance, including revenue growth and profitability, supports this optimistic outlook, although debt levels warrant caution.
The consensus among analysts indicates a bullish outlook for DexCom, supported by recent upgrades and positive financial indicators. The increase in the average price target reflects expectations of continued growth and market performance. However, the company's higher-than-average debt-to-equity ratio introduces a note of caution, potentially moderating the impact of positive analyst ratings on the stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100